Sweden’s Xbrane Lays Out Ranibizumab Ambitions
As Key Biosimilar Trial Affected By COVID-19
Through a partnership with Stada, Sweden’s Xbrane is looking to introduce a biosimilar to Lucentis in major developed markets, including the EU and the US, where the hunt for a commercialization partner continues.
